#news #medical #clinicalresearch #lifesciences #pharma #pharmiweb
Graft-versus-host disease, Cytokine release syndrome, TGN1412, Anti-thymocyte globulin, Form 10-K, Cytokine

Humanigen Elects Dr. Dale Chappell to Board of Directors

On Feb 8, 2021
@pharminews shared
Humanigen Elects Dr. Dale Chappell to Board of Directors https://t.co/HbtRnWGLU4 #news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/p1vUMz7YDq
Open

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced that the Company’s Board ...

www.pharmiweb.com
On Feb 8, 2021
@pharminews shared
Humanigen Elects Dr. Dale Chappell to Board of Directors https://t.co/HbtRnWGLU4 #news #pharma #clinicalresearch #biotech #lifesciences #medical #healthcare #pharmiweb https://t.co/p1vUMz7YDq
Open

Humanigen Elects Dr. Dale Chappell to Board of Directors

Humanigen Elects Dr. Dale Chappell to Board of Directors

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response ...

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

BURLINGAME, Calif. & TUSTIN, Calif. --(BUSINESS WIRE)--Feb. 3, 2021-- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today ...

CytoSorb® Assigned Dedicated Procedure Code in Switzerland

CytoSorb® Assigned Dedicated Procedure Code in Switzerland

MONMOUTH JUNCTION, N.J., Sept. 20, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader using its CytoSorb® bloo...

Humanigen momentum barges on as Covid-19 candidate is selected for NIAID trial

Humanigen momentum barges on as Covid-19 candidate is selected for NIAID trial

One of “Pharma Bro” Martin Shkreli’s former biotechs came back from the dead during the Covid-19 pandemic thanks to its drug candidate targeting cytokine storms. Now, that company has ...

A ‘Human’ Touch vs. COVID-19

A ‘Human’ Touch vs. COVID-19

Four years since its emergence from a bankruptcy, touched off by the arrest of its former CEO, “Pharma Bro” Martin Shkreli, Humanigen is testing whether its engineered antibody or ...

Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study

Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study

Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDA ...

Cytokine Storm

Cytokine Storm

Review Article from The New England Journal of Medicine — Cytokine Storm

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice

Scoring criteria were as follows: dermis (0, normal; 1, mild increased collagen density; 2, marked increased collagen density); hair follicles (0, normal number of approximately 5 per ...

Ruxolitinib shows promise in severe COVID-19

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus ...